Breast cancer treatment faces significant challenges, including off-target toxicity, drug resistance, and the inability to dynamically adjust therapy in response to tumor microenvironment changes. To address these limitations, intelligent drug delivery systems have emerged as a revolutionary approach for controlled and precise breast cancer therapy. This chapter delves into cutting-edge stimuli-responsive nanocarriers. These innovative systems are engineered to boost therapeutic effectiveness and reduce side effects throughout the body. They achieve this by reacting to specific triggers—both internal and external. This responsiveness allows for precise, on-demand drug release, significantly cutting down on overall toxicity. Polymeric nanoparticles are highly effective drug delivery vehicles to carry a large amount of medication and can be easily modified to deliver drugs precisely where they’re needed. Dendrimers enable precise control at the molecular level over how drugs are attached and released. This chapter delves into the design principles, synthesis techniques, and functionalization strategies for both systems, emphasizing their use in breast cancer treatment. Significant advancements in dual or multi-stimuli-responsive platforms are examined, along with recent in vitro and in vivo research that showcases improved therapeutic effectiveness, fewer side effects, and greater patient adherence. Additionally, challenges in clinical translation, including biocompatibility, scalability, and regulatory hurdles, are critically evaluated. Finally, we highlight future directions, including CRISPR-based adaptive systems and synthetic biology-integrated nanocarriers, offering a roadmap toward personalized breast cancer treatment. This chapter underscores how adaptive nanocarriers are redefining precision oncology, bridging the gap between laboratory innovation and real-world therapeutic impact.